Search Images Maps Play YouTube Gmail Drive Calendar More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberWO2005051933 A1
Publication typeApplication
Application numberPCT/IB2004/003829
Publication date9 Jun 2005
Filing date23 Nov 2004
Priority date28 Nov 2003
Publication numberPCT/2004/3829, PCT/IB/2004/003829, PCT/IB/2004/03829, PCT/IB/4/003829, PCT/IB/4/03829, PCT/IB2004/003829, PCT/IB2004/03829, PCT/IB2004003829, PCT/IB200403829, PCT/IB4/003829, PCT/IB4/03829, PCT/IB4003829, PCT/IB403829, WO 2005/051933 A1, WO 2005051933 A1, WO 2005051933A1, WO-A1-2005051933, WO2005/051933A1, WO2005051933 A1, WO2005051933A1
InventorsYatendra Kumar, Vijay Kumar Kaul, Nitu Singh, Gyan Chand Yadav
ApplicantRanbaxy Laboratories Limited
Export CitationBiBTeX, EndNote, RefMan
External Links: Patentscope, Espacenet
An improved process for the synthesis of 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylic acid tert-butyl ester, a key intermediate for oxazolidinone antimicrobials and compounds prepared thereby
WO 2005051933 A1
Abstract
Provided herein are process for the synthesis of the 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylic acid tert-butyl ester, which is a key intermediate in the synthesis of oxazolidinone compounds having antibacterial activity. Also provided herein are processes for preparing oxazolidinone compounds. In addition, compounds prepared by the processes provided herein are also encompassed. Formula (I) and Formula (II).
Claims  (OCR text may contain errors)
We Claim: A process for the preparation of 4-(4-benzyloxy-carbonylamino-2- fluorophenyl)-piperazin- 1 -carboxylic acid tert butyl ester of Formula I,
Formula I comprising the steps of: condensing piperazine with l,2-difluoro-4-nitrobenzene to form a 4-(2-fluoro-4- nitropheyι)-piperazine of Formula II,
Formula II contacting the compound of Formula II with di-tert-butyl carboxylic anhydride to form 4-(2- fluoro-4-nitrophenyl)-piperazine- 1 -carboxylic acid butyl ester of Formula III,
reducing the compound of Formula III to form 4-(4-amino-2-fluorophenyl)-piperazin- 1- carboxylic acid tert-butyl ester of Formula IV,
and reacting the compound of Formula TV with benzylchloroformate to form a compound 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazin- 1 -carboxylic acid tert butyl ester of Formula I. 2. The process of claim 1, wherein the reaction of piperazine with l,
2-difluoro-4- nitrobenzene to form Formula II is earned out in an aromatic hydrocarbon.
3. The process of claim 2, wherein the aromatic hydrocarbon is selected from toluene, xylene, and mixtures thereof.
4. The process of claim 2, wherein the aromatic hydrocarbon is toluene.
5. The process of claim 1, wherein the reaction of piperazine with l,2-difluoro-4- nitrobenzene is carried out at a temperature of about 40 C to about 90 C.
6. The process of claim 5, wherein the reaction of piperazine with l,2-difluoro-4- nitrobenzene is carried out at a temperature of about 80 C to about 90 C.
7. The process of claim 1 , wherein the reaction of a compound of Formula II with di-tert-butoxycarbonyl anhydride to form a compound of Formula III is carried out in an aromatic hydrocarbon.
8. The process of claim 7, wherein the aromatic hydrocarbon is selected from toluene, xylene, and mixtures thereof.
9. The process of claim 8, wherein the aromatic hydrocarbon is toluene.
10. The process of claim 1 , wherein the reduction of a compound of Formula III to form a compound of Formula TV is carried out in an aromatic hydrocarbon.
11. The process of claim 10, wherein the aromatic hydrocarbon is selected from toluene, xylene, and mixtures thereof.
12. The process of claim 11, wherein the aromatic hydrocarbon is toluene.
13. The process of claim 1 wherein the reduction of a compound of Formula III to form a compound of Formula TV is carried out in the presence of a reducing agent.
14. The process of claim 13, wherein the reducing agent is palladium on carbon.
15. The process of claim 1 , wherein the reaction of a compound of Formula IV with benzylchloroformate to form a compound of Formula I is carried out in an organic solvent.
16. The process of claim 15, wherein the organic solvent is toluene.
17. The process of claim 1 , wherein the reaction of a compound of Formula IV with benzylchloroformate is carried out in the presence of an inorganic base.
18. The process of claim 17, wherein the inorganic base is selected from sodium bicarbonate, potassium carbonate, and potassium bicarbonate.
19. The process of claim 18, wherein the inorganic base is sodium bicarbonate.
20. A process for the preparation of oxazolidinone compounds of Formula Id
Formula Id comprising the steps of: a. reacting a compound of Formula I
Formula I with butyl lithium and glycidyl butyrate to form a compound of Formula la, Formula la b. reacting the compound of Formula la with methane sulphonyl chloride, ammonium hydroxide and an acetyl halide of Formula CH3CO-hal, wherein hal is Br, CI or I, to form a compound of Formula lb,
Formula lb c. deprotecting the compound of Formula lb to form a compound of Formula Ic, and
, Formula Ic d. reacting the compound of Formula ic with R-T-(W)o-ι-R12 to form the compound of Formula Id, wherein T is a five- to seven-membered heterocyclic ring, aryl or substituted aryl, bound to the piperazinyl ring via linker W, wherein the heterocyclic ring has at least one heteroatom selected from oxygen, nitrogen and sulfur, and T is further substituted by a group represented by R, wherein R is H, CHO, (Ci-QO-alkyl, F, CI, Br, I, -CN, COR5, COOR5, N(R6R7), CON(R6R7), CH2NO2, NO2, CH2R8, CHR9, -CH=N-OR10, -C=CH-R5, NHCOC(R8R9), NHCOOR10, CH(OAc)2, OR5, SR5, -C(R9)NO2, (Cι-C12)-alkyl substituted with one or more of F, CI, Br, I, OR or SRf, wherein R5 is H, optionally substituted (Cι-C12)-alkyl, (C3-C12)-cycloall yl, aryl, heteroaryl, (Cι-C6)-alkoxy, or (Cι-C6)-alkyl substituted with one or more ofF, Cl, Br, I or OH; R6 and R7 is independently selected from H, optionally substituted (C1- 2)- alkyl, (C3-C12)-cycloalkyl, or (Cι-C6)-alkoxy; R8 and R9 is independently selected from H, (C1-C6)-alkyl, F, CI, Br, (C1.-C12)- alkyl substituted with one or more of F, CI, Br, I, OR5, SR5, N(R6R ) wherein R5, Rό and R7 is the same as defined earlier, R10 is H, optionally substituted (C1-C12)-alkyl, (C3-C12)-cycloalkyl, (C1-C6)-alkoxy, (Cι-C6)-alkyl, aryl, or heteroaryl; and W is CH2, CO, -CH2 NH-, -NHCH2-, -CH2NHCH2-, -CH2-N(RU)CH2-, -CH2(Rn)N-, CH(Rι 1), S, CH2(CO), NH, wherein Rπ is optionally substituted (C1-C12)-alkyl, (C3-Ci2)-cycloalkyl, (C\- C6)-alkoxy, (Cι-C6)-alkyl, aryl or heteroaryl; and R12 is a leaving group.
21. The process of claim 20, wherein the leaving group is fluoro, chloro, bromo, SCH3, -SO2CH3, -SO2CF3 or OC6H5.
22. The process of claim 20, wherein the compound of Formula I is prepared by a process comprising the steps of: a. condensing piperazine with l,2-difluoro-4-nitrobenzene to form a 4-(2-fluoro- 4-nitropheyl)-piperazine of Formula II,
Formula II b. contacting the compound of Formula II with di-tert-butyl carboxylic anhydride to form 4-(2-fluoro-4-nitrophenyl)-piperazine- 1-carboxylic acid butyl ester of Formula III,
c. reducing the compound of Formula III to form 4-(4-amino-2-fiuorophenyl)- piperazin-l-carboxylic acid tert-butyl ester of Formula IN, and
Formula TV d. reacting the compound of Formula TV with benzylchloroformate to form a compound 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazin-l-carboxylic acid tert butyl ester of Formula I.
Formula I 23. A compound prepared by a process comprising the steps of: condensing piperazine with l,2-difluoro-4-nitrobenzene to form a 4-(2-fluoro-4- nitropheyl)-piperazine of Formula II,
Formula II contacting the compound of Formula II with di-tert-butyl carboxylic anhydride to form 4-(2- fluoro-4-nitrophenyl)-piperazine- 1 -carboxylic acid butyl ester of Formula III,
Formula III reducing the compound of Formula III to form 4-(4-amino-2-fluorophenyl)-piperazin- 1 - carboxylic acid tert-butyl ester of Formula IN, Formula IN and reacting the compound of Formula TV with benzylchloroformate. 24. A compound prepared by a process comprising the steps of: a. reacting a compound of Formula I
Formula I with butyl lithium and glycidyl butyrate to form a compound of Formula la,
Formula la b. reacting the compound of Formula la with methane sulphonyl chloride, ammonium hydroxide and an acetyl halide of Formula CH3CO-hal, wherein hal is Br, CI or I, to form a compound of Formula lb,
Formula lb deprotecting the compound of Formula lb to form a compound of Formula Ic, and
Formula Ic d. reacting the compound ofFormula lc with R-T-(W)0-ι-Ri2, wherein T is a five- to seven-membered heterocyclic ring, aryl or substituted aryl, bound to the piperazinyl ring via linker W, wherein the heterocyclic ring has at least one heteroatom selected from oxygen, nitrogen and sulfur, and T is further substituted by a group represented by R, wherein R is H, CHO, (C1-C6)-alkyl, F, CI, Br, I, -CN, COR5, COOR5, N(R6R7), CON(R6R7), CH2NO2, NO2, CH2R8, CHR9, -CH=N-OR10, -C=CH-R5, NHCOC(R8R9), NHCOOR10, CH(OAc)2, OR5, SR5, -C(R9)NO2, (C1-C12)-alkyl substituted with one or more of F, CI, Br, I, OR4 or SR4, wherein R5 is H, optionally substituted (C3-Ci2)-cycloalkyl, aryl, heteroaryl, (C1-C6)-alkoxy, or ( -C^-alkyl substituted with one or more ofF, Cl, Br, I or OH; R6 and R7 is independently selected from H, optionally substituted ( -C12)- alkyl, (C3-C12)-cycloalkyl, or (C1-C6)-alkoxy; R8 and R9 is independently selected from H, (Cι-C6)-alkyl, F, CI, Br, ( -Cπ)- alkyl substituted with one or more of F, CI, Br, I, OR5, SR5, N(R6R7) wherein R5, R6 and R is the same as defined earlier, R10 is H, optionally substituted (Cι-Cι2)-alkyl, (C3-Cι2)-cycloalkyl, (Cι-C6)-alkoxy, (Cι-C6)-alkyl, aryl, or heteroaryl; and W is CH2, CO, -CH2 NH-, -NHCH2-, -CH2NHCH2-, -CH2-N(RU)CH2-, -CH2(Rπ)N-, CH(R, 1), S, CH2(CO), NH, wherein Rπ is optionally substituted (Cι-C12)-alkyl, (C3-Ci2)-cycloalkyl, (Ci- C6)-alkoxy, (C1-C6)-alkyl, aryl or heteroaryl; and R12 is a leaving group.
Description  (OCR text may contain errors)

AN IMPROVED PROCESS FOR THE SYNTHESIS OF 4- (4-BENZYL0XY-CARB0NYLAMIN0-2-FLU0R0PH ENYD -PIPΞRAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER, A KEY INTERMEDIATE FOR OXAZOLIDINONE ANTIMICROBIALS AND COMPOUNDS PREPARED THEREBY

Field of the Invention The present invention relates to processes for the synthesis of the 4-(4-benzyloxy- carbonylamino-2-fluorophenyl)-piperazine-l-carboxylic acid tert-butyl ester of Formula I,

Formula I which is a key intermediate in the synthesis of oxazolidinone compounds having antibacterial 10 activity.

Background of the Invention

Oxazolidinones are a new class of synthetic antimicrobial agents, which kill gram- positive pathogens by inhibiting a very early stage of protein synthesis. Oxazolidinones inhibit the formation of ribosomal initiation complex involving 30S and 50S ribosomes 15 leading to prevention of initiation complex formation. Due to their novel mechanism of action, these compounds are active against pathogens resistant to other clinically useful antibiotics. For example, phenyloxazolodinones and phenyl piperazinyl oxazolidinones have been disclosed as being useful antimicrobial agents effective against human and veterinary pathogens including gram positive and acid-fast organisms. 0 A previosly known general method for the synthesis of the intermediate 4-(4- benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-l-carboxylic acid tert-butyl ester of Formula I has been reported, which comprises reacting piperazine with l,2-difluoro-4- nitrobenzene in acetonitrile to form l-(2-fluoro-4-nitrophenyl)-piρerazine, which is reacted further with di-tert-butoxycarbonyl anhydride in tetrahydrofuran to form 4-(2-fluoro-4- 5 nitrophenyl) piperazin-l-carboxylic acid tert-butyl ester. The resulting nitro compound is reduced with palladium on carbon in methanol and reacted with benzylchloroformate in tetrahydrofuran to form 4-(4-benzyloxycarbonyl amino-2-fluorophenyl)-piperazin-l- carboxylic acid tert-butyl ester of Formula I.

Available methods for the synthesis of compounds of Formula I suffer from a number of limitations and accordingly, are not suitable for commercial production. For example, known methods require the use of acetonitrile, which is highly toxic, inflammable and difficult to handle at commercial scales; and tetrahydrofuran, which is unsafe and burdened with the risk of explosion and fire due to peroxide formation, as well as being an expensive solvent and adds significant factor in the overall cost of preparation of final product. Further, the nitro group reduction is carried out in methanol and tetrahydrofuran and in the presence of ammonium formate-Pd/C catalyst, which is a highly exothermic reaction. This sudden rise in temperature increases the formation of by-products and thereby decreases the overall product yield. In addition, purification of the compound involves column chromatography, which is cumbersome, tedious and not practicable on an industrial scale; the synthesis of the pure compound involves more steps; and the overall yield of the pure compound is poor. Accordingly, there remains a need for an improved, commercially viable process to synthesize oxazolidinones. Summary of the Invention

The process provided herein encompass novel methods for the synthesis of the 4-(4- benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-l-carboxylic acid tert-butyl ester of Formula I, which provides improvements over prior methods of synthesis. In one aspect, there is provided a process for the synthesis of highly pure 4-(4- benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-l-carboxylic acid tert-butyl ester of Formula I,

Formula I comprising the steps of: condensing piperazine with l,2-difluoro-4-nitrobenzene to form l-(2-fluoro-4-nitro-phenyl)- piperazine of Formula II,

contacting the compound of Formula II with di-tert-butoxycarbonyl anhydride to form 4- (2- fluoro-4-nitrophenyl)-piperazine 1-carboxylic acid tert-butyl ester of Formula III,

reducing the compound of Formula III to form 4-(4-amino-2-fluorophenyl)-piperazin-l- carboxylic acid tert-butyl ester of Formula IV,

Formula IV and reacting the compound of Formula IN with benzylchloroformate to form 4-(4-benzyloxy- carbonylamino-2-fluorophenyl)-piperazine- 1-carboxylic acid tert-butyl ester of Formula I. In one aspect, the step of condensing piperazine with l,2-difluoro-4-nitrobenzene is carried out in an aromatic hydrocarbon, such as toluene, xylene and the like, or mixtures thereof, and at a temperature of, for example, about 40 C to about 90 C, or from about 80 C to about 90 C.

In another aspect, the step of contacting the compound of Formula II with di-tert- butoxycarbonyl anhydride is carried out in an aromatic hydrocarbon, such as toluene, xylene and the like, or mixtures thereof.

In yet another aspect, the step of reducing the compound of Formula III is carried out in the presence of a reducing agent, such as palladium on carbon, and in an aromatic hydrocarbon, such as toluene, xylene and the like, or mixtures thereof. In another aspect, the reaction of the compound of Formula IN with benzylchloroformate is carried out in the presence of an inorganic base, such as sodium bicarbonate, potassium carbonate or potassium bicarbonate, in an organic solvent, such as toluene, and at a temperature of about 20 C to about 40 C. Processes provided herein are advantageous over prior methods because, among other reasons, involve fewer steps, as some steps are carried out in situ; the purification of compound need not involve column chromatography, which thus makes the processes convenient to operate at commercial scale; the reduction may be carried out in toluene in the presence of Pd/C, avoiding the exothermicity of the reaction and by-product formation; and the processes need not involve the use of tetrahydrofuran, a material associated with a high risk of fire and explosion. Oxazolidinone compounds can be prepared from compounds of Formula I using, for example, using methods disclosed in U.S. Patent No. 6,734,307 and PCT Publication Nos. WO 02/06278, WO 03/007870, WO 03/097059, WO04/089944 and WO04/14392, which are incorporated herein by reference. Scheme I below shows a synthetic route starting from a compound of Formula I to oxazolidinone compounds.

Formula lb

Formula lc

Formula Id Scheme I A compound of Formula I

Formula I can be reacted with a base, e.g., butyl lithium, and glycidyl butyrate to form a compound of

Formula la.

Formula la

The compound of Formula la can be reacted with methane sulphonyl chloride, followed by ammonium hydroxide, and finally acetyl halide of Formula CH3CO-hal (wherein hal is Br, CI or I) to form a compound of Formula lb.

Formula lb

The compound of Formula lb can be deprotected to form a compound of Formula Ic.

The compound of Formula Ic can be reacted with R-T-(W)0-ι-R12 to form a compound of Formula Id

Formula Id wherein T can be a five- to seven-membered heterocyclic ring, aryl or substituted aryl, bound to the piperazinyl ring via linker W, wherein the heterocyclic ring can have at least one heteroatom selected from oxygen, nitrogen and sulfur. Preferred forms of T can be aryl and five-membered heteroaryl, which can be further substituted by a group represented by R, wherein R can be H, CHO, (Cι-C6)-alkyl, F, CI, Br, I, -CN, COR5, COOR5, N(R6R7), CON(RδR7), CH2NO2, NO2, CH2R8, CHR9, -CH=N-ORιo, -C=CH-R5, NHCOC(R8R9), NHCOOR10, CH(OAc)2, OR5, SR5, -C(R9)NO2, (C Ci^-alkyl substituted with one or more of F, CI, Br, I, OR4 or SR4, wherein R5 can be H, optionally substituted (C1-C1 )-alkyl, (C3-Cι2)-cycloalkyl, aryl, heteroaryl, ( -C^-alkoxy, or (C1-C6)-alkyl substituted with one or more of F, CI, Br, I or OH; R6 and R7 can be independently selected from H, optionally substituted (CVC1 )-alkyl, (C3-C12)-cycloalkyl, or ( -C^-alkoxy; R8 and R9 can be independently selected from H, (Cι-C6)-alkyl, F, CI, Br, (C1-C12)- alkyl substituted with one or more of F, CI, Br, I, OR5, SR5, N(R6R7) wherein R5, Re and R7 can be the same as defined earlier, R10 is H, optionally substituted ( -Cn)- alkyl, (C3-C12)-cycloalkyl, (C!-C6)-alkoxy, (Cι-C6)-alkyl, aryl, or heteroaryl; W can be selected from CH2, CO, -CH2 NH-, -NHCH2-, -CH2NHCH2-, -CH2-N(Rι ι)CH2-, -CH2(Rn)N-, CH(Rπ), S, CH2(CO), NH, wherein Rπ can be optionally substituted (C1-C12)-alkyl, (C3-C12)-cycloalkyl, (Cι-C6)- alkoxy, ( -C^-alkyl, aryl or heteroaryl; and R12 can be a suitable leaving group well known to one of ordinary skill in the art, for example, fluoro, chloro, bromo, SCH3, -SO2CH3, -SO2CF3 or OC6H5 and the like. Another aspect encompasses compounds prepared by processes provided herein. Detailed Description of the Invention

In the following section preferred embodiments are described in a way to illustrate the disclosure. However, this does not limit the scope of the present invention.

EXAMPLE Preparation of 4-(4-benzyloxy-carbonylamino-2-fluorophenyl -piperazine- 1 - carboxylic acid tert-butyl ester of Formula I

Piperazine (0.77 mol, 66.2 g) was mixed with toluene (500 mL) and stirred at room temperature and subsequently stirred at 50 C until a homogenous solution was obtained. 1,2- difluoro-4-nitrobenzene (0.314 mol, 50 g) was added to the piperazine/toluene solution and the reaction mixture was stirred at 80-90 C for 3-6 hours. The reaction mixture then was cooled to 40-45 C and diluted with deionized water. The organic layer was separated and about 250-350 mL of toluene was evaporated off under reduced pressure at 40 C. Di-tert- butoxycarbonyl anhydride (0.334mol, 75 g) was then added dropwise to the reaction mixture at room temperature. The resulting reaction mixture was stirred at room temperature for 1-2 hours and then further diluted with hexane (200 mL) and stirred for 15-20 minutes at room temperature. The solid product formed in the reaction mixture was filtered, washed with hexane (150 mL), and dried under reduced pressure at 60-70C to yield 4-(2-fluoro-4- nitrophenyl)-piperazine- 1-carboxylic acid tert butyl ester of Formula III. Yield = 1.8-1.9 (w\w); Purity = 96-98% by HPLC.

The compound of Formula III (0.246 mol, 80 g) was added to toluene (800 mL) followed by the addition of palladium on carbon (4 g) at room temperature with continuous stirring. Hydrogen gas was bubbled into the resulting reaction mixture at a pressure of 72 psi. The reaction mixture was stirred for 12-16 hours and then diluted with toluene (150 mL). The reaction mixture was filtered through a celite pad and washed with toluene (200 mL). Sodium bicarbonate solution was added to the reaction mixture at room temperature with continuous stirring. Benzyl chloroformate (0.310 mol, 103 g) was added dropwise to the reaction mixture with continuous stirring for 2-3 hours. Ethyl acetate (1600 mL) was added to the reaction mixture and stirred for about 30 minutes followed by addition of deionized water (400 mL). The organic layer was separated and the solvent was removed under reduced pressure. The semi-solid product was washed with hexane (350 mL) to obtain 4-(4-benzyloxy- carbonylamino-2-fluorophenyl)-piperazine- 1-carboxylic acid tert-butyl ester of Formula I as a solid. Yield = 1.16-1.23 (w/w); Purity = 97-99% by HPLC.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
WO1993023384A1 *21 Apr 199325 Nov 1993The Upjohn CompanyOxazolidinones containing a substituted diazine moiety and their use as antimicrobials
WO1997030981A1 *18 Feb 199728 Aug 1997Pharmacia & Upjohn CompanyAzolyl piperazinyl phenyl oxazolidinone antimicrobials
WO1998001447A1 *1 Jul 199715 Jan 1998Zeneca LimitedPyridyl-piperazinyl-phenyl-oxazolidinone derivatives and their use as antibacterials
WO2002006278A1 *16 Jul 200124 Jan 2002Ranbaxy Laboratories LimitedOxazolidinone derivatives as antimicrobials
WO2002048139A2 *14 Dec 200120 Jun 2002Pharmacia & Upjohn CompanyOxazolidinone photoaffinity probes
WO2003002560A1 *24 Jun 20029 Jan 2003Laboratorios Vita, S.A.New derivatives of oxazolidinones as antibacterial agents
WO2003007870A2 *10 May 200230 Jan 2003Ranbaxy Laboratories LimitedOxazolidinone derivatives as antimicrobials
WO2004018439A1 *21 Aug 20034 Mar 2004Orchid Chemicals & Pharmaceuticals LtdNovel antibacterial agents
Non-Patent Citations
Reference
1 *DU YU ET AL: "Synthesis and antibacterial activity of linezolid analogUES" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 12, 2002, pages 857-859, XP002245432 ISSN: 0960-894X
2 *IN HWA CHUNG ET AL: "SYNTHESIS AND IN VITRO ANTIBACTERIAL ACTIVITY OF QUATERNARY AMMONIUM CEPHALOSPORIN DERIVATIVES BEARING OXAZOLIDINONE MOIETY" ARCHIVES OF PHARMACAL RESEARCH, NATL. FISHERIES UNIVERSITY, PUSAN, KR, vol. 22, no. 6, 1999, pages 579-584, XP001037701 ISSN: 0253-6269
3 *PAE A N ET AL: "3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 9, no. 18, 20 September 1999 (1999-09-20), pages 2685-2690, XP004179952 ISSN: 0960-894X
4 *PAE A N ET AL: "Synthesis and In Vitro Activity of new Oxazolidinone Antibacterial Agents Having Substituted Isoxazoles" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 9, 1999, pages 2679-2684, XP002301080 ISSN: 0960-894X
5 *TUCKER J A ET AL: "PIPERAZINYL OXAZOLIDINONE ANTIBACTERIAL AGENTS CONTAINING A PYRIDINE, DIAZENE, OR TRIAZENE HETEROAROMATIC RING" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 19, 1998, pages 3727-3735, XP001203467 ISSN: 0022-2623
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
WO2010042887A2 *9 Oct 200915 Apr 2010Trius TherapeuticsMethods for preparing oxazolidinones and compositions containing them
WO2010042887A3 *9 Oct 200924 Jun 2010Trius TherapeuticsMethods for preparing oxazolidinones and compositions containing them
EP2757104A1 *9 Oct 200923 Jul 2014Trius TherapeuticsCompounds used in the synthesis of oxazolidinones
US84263893 Feb 201023 Apr 2013Trius Therapeutics, Inc.Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
US858076725 May 201012 Nov 2013Trius Therapeutics, Inc.Oxazolidinone containing dimer compounds, compositions and methods to make and use
US86042099 Oct 200910 Dec 2013Trius Therapeutics, Inc.Methods for preparing oxazolidinones and compositions containing them
US8778412 *5 Nov 201015 Jul 2014Aerpio Therapeutics Inc.Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
US899997121 Aug 20147 Apr 2015Aerpio Therapeutics Inc.Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
US916304315 Apr 201320 Oct 2015Dong-A St Co., Ltd.Oxazolidinone derivatives
US927893022 Feb 20158 Mar 2016Aerpio Therapeutics, Inc.Methods for increasing the stabilization of hypoxia inducible factor-α
US932808725 Nov 20133 May 2016Merck Sharp & Dohme Corp.Methods for preparing oxazolidinones and compositions containing them
US954032616 Apr 201510 Jan 2017Aerpio Therapeutics, Inc.Prolyl hydroxylase inhibitors
US20110111058 *5 Nov 201012 May 2011Robert ShalwitzMethods for increasing the stabilization of hypoxia inducible factor-1 alpha
US20150157617 *22 Feb 201511 Jun 2015Aerpio Therapeutics Inc.Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
Classifications
International ClassificationC07D263/20, C07D295/205
Cooperative ClassificationC07D263/20, C07D295/205
European ClassificationC07D263/20, C07D295/205
Legal Events
DateCodeEventDescription
9 Jun 2005AKDesignated states
Kind code of ref document: A1
Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
9 Jun 2005ALDesignated countries for regional patents
Kind code of ref document: A1
Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
3 Aug 2005121Ep: the epo has been informed by wipo that ep was designated in this application
30 May 2006NENPNon-entry into the national phase in:
Ref country code: DE
30 May 2006WWWWipo information: withdrawn in national office
Country of ref document: DE
20 Dec 2006122Ep: pct app. not ent. europ. phase